MT Newswires
Tempus AI, Merck Collaborate on AI-Driven Precision Medicine
âž–
AI Sentiment
Neutral
5/10
- Home
- MRK
as of 03-03-2026 10:05am EST
$119.00
$2.41
-1.99%
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | RAHWAY |
| Market Cap: | 268.7B | IPO Year: | 1994 |
| Target Price: | $123.21 | AVG Volume (30 days): | 11.1M |
| Analyst Decision: | Buy | Number of Analysts: | 14 |
| Dividend Yield: | Dividend Payout Frequency: | quarterly | |
| EPS: | 7.28 | EPS Growth: | 8.01 |
| 52 Week Low/High: | $75.40 - $125.14 | Next Earning Date: | 05-05-2026 |
| Revenue: | $65,011,000,000 | Revenue Growth: | 1.31% |
| Revenue Growth (this year): | 3.66% | Revenue Growth (next year): | 5.28% |
| P/E Ratio: | 16.69 | Index: | |
| Free Cash Flow: | 12.4B | FCF Growth: | -31.70% |
AI-Powered MRK Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 15 hours ago
AI Recommendation
hold
Model Accuracy: 71.08%
71.08%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Merck & Company Inc. (new) (MRK)
Guindo Chirfi
Sell
Chief Marketing Officer
MRK Feb 12, 2026
Avg Cost/Share
$121.46
Shares
10,000
Total Value
$1,214,562.00
Owned After
60,615.127
SEC Form 4
Zachary Jennifer
Sell
EVP, General Counsel
MRK Feb 9, 2026
Avg Cost/Share
$119.15
Shares
121,573
Total Value
$14,485,690.41
Owned After
68,915.671
Guindo Chirfi
Sell
Chief Marketing Officer
MRK Feb 9, 2026
Avg Cost/Share
$118.41
Shares
10,000
Total Value
$1,184,101.00
Owned After
60,615.127
SEC Form 4
Williams David Michael
Sell
EVP,Chief Info&Digital Officer
MRK Feb 6, 2026
Avg Cost/Share
$121.91
Shares
5,000
Total Value
$609,525.00
Owned After
30,837.743
SEC Form 4
Oosthuizen Johannes Jacobus
Sell
President, U.S. Market
MRK Feb 6, 2026
Avg Cost/Share
$121.87
Shares
15,000
Total Value
$1,827,991.50
Owned After
21,197.389
SEC Form 4
DeLuca Richard R.
Sell
EVP&Pres, Merck Animal Heallth
MRK Feb 6, 2026
Avg Cost/Share
$120.92
Shares
37,685
Total Value
$4,557,024.71
Owned After
160,173.834
SEC Form 4
Guindo Chirfi
Sell
Chief Marketing Officer
MRK Feb 5, 2026
Avg Cost/Share
$121.88
Shares
20,000
Total Value
$2,437,676.00
Owned After
60,615.127
SEC Form 4
Litchfield Caroline
Sell
EVP & CFO
MRK Feb 4, 2026
Avg Cost/Share
$119.61
Shares
41,997
Total Value
$5,023,311.57
Owned After
90,192.194
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Guindo Chirfi | MRK | Chief Marketing Officer | Feb 12, 2026 | Sell | $121.46 | 10,000 | $1,214,562.00 | 60,615.127 | |
| Li Dean Y | MRK | Executive VP & President, MRL | Feb 10, 2026 | Sell | $117.52 | 10,235 | $1,202,843.81 | 92,035.05 | |
| Zachary Jennifer | MRK | EVP, General Counsel | Feb 9, 2026 | Sell | $119.15 | 121,573 | $14,485,690.41 | 68,915.671 | |
| Guindo Chirfi | MRK | Chief Marketing Officer | Feb 9, 2026 | Sell | $118.41 | 10,000 | $1,184,101.00 | 60,615.127 | |
| Williams David Michael | MRK | EVP,Chief Info&Digital Officer | Feb 6, 2026 | Sell | $121.91 | 5,000 | $609,525.00 | 30,837.743 | |
| Oosthuizen Johannes Jacobus | MRK | President, U.S. Market | Feb 6, 2026 | Sell | $121.87 | 15,000 | $1,827,991.50 | 21,197.389 | |
| DeLuca Richard R. | MRK | EVP&Pres, Merck Animal Heallth | Feb 6, 2026 | Sell | $120.92 | 37,685 | $4,557,024.71 | 160,173.834 | |
| Guindo Chirfi | MRK | Chief Marketing Officer | Feb 5, 2026 | Sell | $121.88 | 20,000 | $2,437,676.00 | 60,615.127 | |
| Li Dean Y | MRK | Executive VP & President, MRL | Feb 4, 2026 | Sell | $118.77 | 15,087 | $1,791,824.15 | 92,035.05 | |
| Litchfield Caroline | MRK | EVP & CFO | Feb 4, 2026 | Sell | $119.61 | 41,997 | $5,023,311.57 | 90,192.194 |
Latest Merck & Company Inc. (new) News
MRK Breaking Stock News: Dive into MRK Ticker-Specific Updates for Smart Investing
Business Wire
Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision Medicine
📈
AI Sentiment
Highly Positive
9/10
MT Newswires
Wolfe Adjusts Price Target on Merck to $142 From $135, Maintains Outperform Rating
📊
AI Sentiment
Positive
6/10
GlobeNewswire
MXene Industry Research Report 2026: Market to Grow at a CAGR of 35.6% to 2032, Driven by EV & Charging Infrastructure, Water Treatment Applications and High-Performance Aerospace & Defense Systems
📈
AI Sentiment
Highly Positive
9/10
GlobeNewswire
AI in Pharma Manufacturing Market Research 2026-2040: Pfizer, Moderna, Novartis, Merck, and Sanofi are Integrating AI Into Their Operations As the Sector Evolves Towards Pharma 4.0
📈
AI Sentiment
Highly Positive
9/10
Zacks
BMY Gains 11.4% in a Month: Should You Buy, Sell or Hold the Stock?
📈
AI Sentiment
Highly Positive
8/10
Compare MRK vs Leading Stocks
See how MRK stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "MRK Merck & Company Inc. (new) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.